


Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01

AMENDMENTS TO THE CLAIMS

RECEIVED
 CENTRAL FAX CENTER

JUL 07 2006

1. (Currently Amended) A compound represented by the structural formula (I):



or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein in Formula (I) above:

X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH₂-, -CH(alkyl)- and -C(alkyl)₂-;

Q¹ and Q² can be the same or different and each is independently selected from the group consisting of H, -G₁-(C₀₁-C₃₀ alkylene)-G, -OR⁶, -OC(O)R⁶, -OC(O)OR⁹, -OC(O)NR⁶R⁷ and -L-M;

Q³ is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -G₁-(C₀₁-C₃₀ alkylene)-G, -OR⁶, -(C₀₁-C₁₀ alkylene)-OR⁶, -C(O)R⁶, -(C₀₁-C₁₀ alkylene)-C(O)R⁶, -C(O)OR⁶, -(C₀₁-C₁₀ alkylene)-C(O)OR⁶, -OC(O)R⁶, -(C₀₁-C₁₀ alkylene)-OC(O)R⁶, -OC(O)OR⁹, -(C₀₁-C₁₀ alkylene)-OC(O)OR⁹, -CH=CH-C(O)R⁶, -CH=CH-C(O)OR⁶, -C≡C-C(O)OR⁶, -C≡C-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-C(O)OR⁶, -CN, -O-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -O-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₀₁-C₁₀ alkylene)-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N₃, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N=N⁺, -OC(O)-(C₁-C₁₀ alkylene)-C(O)OR⁶, -C(O)NR⁶R⁷, -(C₀₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -OC(O)NR⁶R⁷, -(C₀₁-C₁₀ alkylene)-OC(O)NR⁶R⁷, -NO₂, -NR⁶R⁷, -(C₀₁-C₁₀ alkylene)-NR⁶R⁷, -O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹,

Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01

-NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹, -N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷,
 -C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹, -O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
 -OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl), -P(O)(OR¹⁰)₂,
 -(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy,
 alkoxyacetylalkoxy, alkoxyaryalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl,
 aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy,
 heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl,
 heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

Q⁴ is 1 to 5 substituents independently selected from the group consisting of alkyl,
 alkenyl, alkynyl, -G-, -(C₀₁-C₃₀ alkylene)-G, -OR⁶, -(C₀₁-C₁₀ alkylene)-OR⁶, -C(O)R⁶,
 -(C₀₁-C₁₀ alkylene)-C(O)R⁶, -C(O)OR⁶, -(C₀₁-C₁₀ alkylene)-C(O)OR⁶, -OC(O)R⁶,
 -(C₀₁-C₁₀ alkylene)-OC(O)R⁶, -OC(O)OR⁹, -(C₀₁-C₁₀ alkylene)-OC(O)OR⁹, -CH=CH-C(O)R⁶,
 -CH=CH-C(O)OR⁶, -C≡C-C(O)OR⁶, -C≡C-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-OR⁶,
 -O-(C₁-C₁₀ alkylene)-C(O)R⁶, -O-(C₁-C₁₀ alkylene)-C(O)OR⁶, -CN,
 -O-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷, -O-C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₀₁-C₁₀ alkylene)-
 C(O)NR⁶NR⁷C(O)OR⁶, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N₃, -O-(C₁-C₁₀ alkylene)-C(O)(aryl)-N₃,
 -N=N, -OC(O)-(C₁-C₁₀ alkylene)-C(O)OR⁶, -C(O)NR⁶R⁷, -(C₀₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
-OC(O)NR⁶R⁷, -(C₀₁-C₁₀ alkylene)-OC(O)NR⁶R⁷, -NO₂, -NR⁶R⁷, -(C₀₁-C₁₀ alkylene)-NR⁶R⁷,
 -O-(C₂-C₁₀ alkylene)-NR⁶R⁷, -NR⁶C(O)R⁷, -NR⁶C(O)OR⁹,
 -NR⁶C(O)NR⁷R⁸, -NR⁶S(O)₀₋₂R⁹, -N(S(O)₀₋₂R⁹)₂, -CHNOR⁶, -C(O)NR⁶R⁷,
 -C(O)NR⁶NR⁶R⁷, -S(O)₀₋₂NR⁶R⁷, -S(O)₀₋₂R⁹, -O-C(O)-(C₁-C₁₀ alkylene)-C(O)NR⁶R⁷,
 -OC(O)-(C₁-C₁₀ alkylene)-NR⁶C(O)O-(alkylaryl), -P(O)(OR¹⁰)₂,
 -(C₁-C₁₀ alkylene)-OSi(alkyl)₃, -CF₃, -OCF₃, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy,
 alkoxyacetylalkoxy, alkoxyaryalkoxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl,
 aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy,
 heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl,
 heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and -L-M;

{W0283016.1}

Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01

Q^5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, $-G_1$, $-(C_{01}-C_{30} \text{ alkylene})-G$, $-OR^6$, $-(C_{01}-C_{10} \text{ alkylene})-OR^6$, $-C(O)R^6$, $-(C_{01}-C_{10} \text{ alkylene})-C(O)R^6$, $-C(O)OR^6$, $-(C_{01}-C_{10} \text{ alkylene})-C(O)OR^6$, $-OC(O)R^6$, $-(C_{01}-C_{10} \text{ alkylene})-OC(O)R^6$, $-OC(O)OR^9$, $-(C_{01}-C_{10} \text{ alkylene})-OC(O)OR^9$, $-CH=CH-C(O)R^6$, $-CH=CH-C(O)OR^6$, $-C\equiv C-C(O)OR^6$, $-C\equiv C-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-OR^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)R^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-CN$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-O-C(O)NR^6NR^7C(O)OR^6$, $-O-(C_{01}-C_{10} \text{ alkylene})-C(O)NR^6NR^7C(O)OR^6$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)(\text{aryl})-N_3$, $-O-(C_1-C_{10} \text{ alkylene})-C(O)(\text{aryl})-N=N^+$, $-OC(O)-(C_1-C_{10} \text{ alkylene})-C(O)OR^6$, $-C(O)NR^6R^7$, $-(C_{01}-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-OC(O)NR^6R^7$, $-(C_{01}-C_{10} \text{ alkylene})-OC(O)NR^6R^7$, $-NO_2$, $-NR^6R^7$, $-(C_{01}-C_{10} \text{ alkylene})-NR^6R^7$, $-O-(C_2-C_{10} \text{ alkylene})-NR^6R^7$, $-NR^6C(O)R^7$, $-NR^6C(O)OR^9$, $-NR^6C(O)NR^7R^8$, $-NR^6S(O)_{0-2}R^9$, $-N(S(O)_{0-2}R^9)_2$, $-CHNOR^6$, $-C(O)NR^6R^7$, $-C(O)NR^6NR^6R^7$, $-S(O)_{0-2}NR^6R^7$, $-S(O)_{0-2}R^9$, $-O-C(O)-(C_1-C_{10} \text{ alkylene})-C(O)NR^6R^7$, $-OC(O)-(C_1-C_{10} \text{ alkylene})-NR^6C(O)O-(\text{alkylaryl})$, $-P(O)(OR^{10})_2$, $-(C_1-C_{10} \text{ alkylene})-OSi(\text{alkyl})_3$, $-CF_3$, $-OCF_3$, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyaryloxy, alkoxyiminoalkyl, alkylidioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and $-L-M$;


wherein optionally one or more carbon atoms of the $-(C_{01}-C_{30} \text{ alkylene})$ - radical of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is independently replaced by $-O-$, $-C(O)-$, $-CH=CH-$, $-C\equiv C-$, $-N(\text{alkyl})-$, $-N(\text{alkylaryl})-$ or $-NH-$;

G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and $-S(O)_2-OH$, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with $-L-M$;

{W0283016.1}


Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01

L is selected from the group consisting of









wherein Me is methyl;

M is selected from the group of moieties consisting of



Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01



pharmaceutically acceptable salts of the moieties (M1) to (M9) and free acids of the moieties (M1) to (M9);

R^2 and R^3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;

R^6 , R^7 and R^8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and

each R^9 is independently alkyl, aryl or arylalkyl.

{W0283016.1}

Application No. 10/792,346
Amendment dated July 7, 2006
Attorney Docket No. CV06038US01

each R^{10} is independently H or alkyl;

q is 0 or 1;

r is 0 or 1;

m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;

x1 is 1 to 10;

x2 is 1 to 10;

x3 is 1 to 10;

x4 is 1 to 10;

x5 is 1 to 10;

x6 is 1 to 10; and

x7 is 1 to 10;

x8 is 1 to 10;

x9 is 1 to 10;

x10 is 1 to 10; and

x11 is 1 to 10;

with the proviso that at least one of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is -L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with -L-M, and

wherein each of the above alkyl, alkenyl, alkynyl, alkylene, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxyaryloxy, alkoxyiminoalkyl, alkylidyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaryloxy, arylalkoxyalkoxy, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, or heterocyclylalkoxy groups, when present, is independently substituted or unsubstituted.


2. (Original) The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is -CH₂-.

{W0283016.1}

Application No. 10/792,346
Amendment dated July 7, 2006
Attorney Docket No. CV06038US01

3. (Original) The compound according to claim 1, wherein m, n and r are each zero, q is 1, p is 2, and Z is $-\text{CH}_2-$, Q^1 is $-\text{OR}^6$, wherein R^6 is hydrogen and Q^5 is fluorine.
4. (Currently Amended) The compound according to claim 1, wherein R^2 and R^3 are each preferably hydrogen.
5. (Original) The compound according to claim 1, wherein Q^1 and Q^2 are each independently selected from the group consisting of $-\text{OR}^6$, $-\text{O}(\text{CO})\text{R}^6$, $-\text{O}(\text{CO})\text{OR}^9$ and $-\text{O}(\text{CO})\text{NR}^6\text{R}^7$.
6. (Original) The compound according to claim 1, wherein Q^4 is halo or $-\text{OR}^6$.
7. (Original) The compound according to claim 1, wherein Q^1 is $-\text{OR}^6$ wherein R^6 is H.
8. (Original) The compound according to claim 1, wherein Q^1 , Q^2 , Q^3 , Q^4 or Q^5 is $-\text{L-M}$.
9. (Currently Amended) The compound according to claim 1, wherein Q^1 , Q^2 , Q^3 , Q^4 or Q^5 is -G or $-(\text{C}_{01}-\text{C}_{30} \text{ alkylene})-\text{G}$.
10. (Withdrawn) The compound according to claim 1, wherein G is selected from the group consisting of:

Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01



wherein R, R^a and R^b can be the same or different and each is independently selected from the group consisting of H, -OH, halo, -NH₂, azido, alkoxyalkoxy or -W-R³⁰;

W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R³¹)-, -NH-C(O)-N(R³¹)- and -O-C(S)-N(R³¹)-;

R^{2a} and R^{6a} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;

R^{3a}, R^{4a}, R^{5a}, R^{7a}, R^{3b} and R^{4b} can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, -C(O)alkyl and -C(O)aryl;

R³⁰ is independently selected from the group consisting of R³²-substituted T, R³²-substituted-T-alkyl, R³²-substituted-alkenyl, R³²-substituted-alkyl, R³²-substituted-cycloalkyl and R³²-substituted-cycloalkylalkyl;

R³¹ is independently selected from the group consisting of H and alkyl;


T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;

R³² is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF₃, -NO₂, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -N(CH₃)₂, -C(O)-NHalkyl, -C(O)-N(alkyl)₂, -C(O)-alkyl, -C(O)-alkoxy and pyrrolidinylcarbonyl; or R³² is a covalent bond and R³¹, the nitrogen to which it is

Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01

attached and R³² form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group.

11. (Withdrawn) The compound according to claim 10, wherein G is selected from:




wherein Ac is acetyl and Ph is phenyl.


Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01

12. (Currently Amended) The compound according to claim 1, wherein optionally one or more carbon atoms of the $-(C_{61}-C_{30} \text{ alkylene})-$ radical of Q^1 , Q^2 , Q^3 , Q^4 and Q^5 is independently replaced by $-O-$.


13. (Original) The compound according to claim 1, wherein L is



14. (Original) The compound according to claim 1, wherein L is




15. The compound according to claim 1, wherein M is



(M1) or pharmaceutically acceptable salts thereof.


16 The compound according to claim 1, wherein M is



(M2) or pharmaceutically acceptable salts thereof.


Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01

17. The compound according to claim 1, wherein M is




(M3) or pharmaceutically acceptable salts thereof.

18. The compound according to claim 1, wherein M is



(M4) or pharmaceutically acceptable salts thereof.

19. The compound according to claim 1, wherein M is







(M7) or pharmaceutically acceptable salts thereof.

20. The compound according to claim 1, which is selected from the group consisting of

{W0283016.1}

Application No. 10/792,346
 Amendment dated July 7, 2006
 Attorney Docket No. CV06038US01



21. (Currently Amended) A pharmaceutical composition for the treatment or prevention of a ~~vascular condition~~ atherosclerosis, hypercholesterolemia, sitosterolemia, diabetes mellitus, obesity, stroke, lowering a concentration of a ~~cholesterol~~ phytosterol or 5 α -stanol in plasma of a mammal, ~~preventing~~ treating demyelination or treating Alzheimer's disease and/or

Application No. 10/792,346
Amendment dated July 7, 2006
Attorney Docket No. CV06038US01

regulating levels of amyloid β peptides in a subject comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.

22. (Original) A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.

23. (Currently Amended) A method of treating ~~or preventing a vascular condition~~ atherosclerosis, hypercholesterolemia, sitosterolemia, diabetes mellitus, obesity, stroke, lowering a concentration of ~~a cholesterol, phytosterol~~ or 5 α -stanol in plasma of a mammal, ~~preventing treating demyelination~~ or treating Alzheimer's disease or regulating a level of an amyloid β peptide in a subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 1.

24. (Original) A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 1.